IRCT20220408054450N1已完成4 期
To compare the safety and efficacy of Dapagliflozin and Glimepiride as add-on to Metformin in patients with type 2 diabetes.
Bahria University Medical & Dental College0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 45 years 至 55 years（—）
- 性别
- All
入选标准
- •normal baseline levels of LFT, RFT, lipid profile, and white blood cell count (WBC).
- •The fasting plasma glucose (FBG) levels of all recruited participants to be = 126 mg/dL
- •hemoglobin A1c levels to be >7-10%
- •1500 mg/day metformin monotherapy for last 3 to 6 months.
- •Age of 45-55 years old
- •Either gender
排除标准
- •Hypertension
- •Decompensated or acute congestive heart failure
- •Estimated glomerular filtration rate (egfr) less than 60 ml/min/1.73 m2
- •Left ventricular ejection fraction (levf) less than 40%
- •Liver impairment
- •Terminal illness, or cancer
- •Unwilling to give consent or participate
研究者
相似试验
尚未招募
4 期
Effectiveness and Safety of diabetic drugs in diabetic participantsCTRI/2024/07/071196Dr Manu Arya
尚未招募
不适用
Dapagliflozin in Heart FailureCTRI/2022/11/047725Sanjay Kumar R
已完成
不适用
Evaluation of efficiency and safety of dapagliflozin in treating of type 2 diabetes mellitustype 2 diabetesJPRN-UMIN000023681Juntendo University Urayasu Hospital30
尚未招募
不适用
Benefits and side effects of Dapagliflozin medicine in diabetic patients with kidney disease.CTRI/2022/09/045596Maulana Azad Medical College Delhi
尚未招募
不适用
Dapagliflozin is a licensed medicine used for reducing blood sugar in people with diabetes and this study will test whether it can also reduce the stiffness in the liver which commonly occurs in diabetes.CTRI/2019/05/019286Dr Shashi Panicker